OpenAI: Using AI agents to uncover new leads in biological data

Commenters debated OpenAI's push to use AI agents to surface "new leads" in biological data, with some voicing skepticism about hype and marketing. SimianSci called the effort a half-baked attempt to prop up cooling enthusiasm, while vatsachak and suddenlybananas criticized promotional framing and trivial metrics like report-format preference. RomanPushkin expressed cautious hope that AI could produce truly valuable discoveries even at the cost of "stealing joy" from researchers, and dude250711 mocked the company for seeking outsized valuation for partial effort.

Opinion split sharply over where AI can help and what the real bottlenecks are. Jostmey and pebbly_bread suggested AI's biggest value is navigating study complexity, regulation, and improving model fidelity to reduce false leads, whereas qurren and throw310822 emphasized the need for higher-quality, not just more, hypotheses. I000 argued AI could address gaps where causal mechanisms are poorly understood, while moregrist and others stressed that efficacy, toxicity, and limited high-quality training data are the true constraints; busyant pushed back on moregrist’s characterization of combinatorial chemistry as a former "gold standard." Noaidi warned that systemic issues - diet, affordability, and industry incentives - could still derail promising leads.